Publisher Correction: Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study.

Nat Metab

Synlogic, Inc., Cambridge, MA, USA.

Published: September 2022

Download full-text PDF	Source
http://dx.doi.org/10.1038/s42255-022-00635-4	DOI Listing

Publication Analysis

publisher correction

correction safety

safety pharmacodynamics

pharmacodynamics engineered

engineered coli

coli nissle

nissle treatment

treatment phenylketonuria

phenylketonuria first-in-human

first-in-human phase

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!